Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide

被引:69
作者
Braga, Antonio [1 ,2 ]
Mora, Paulo [1 ,3 ]
de Melo, Andreia Cristina [3 ]
Nogueira-Rodrigues, Angelica [4 ]
Amim-Junior, Joffre [2 ]
Rezende-Filho, Jorge [2 ]
Seckl, Michael J. [5 ]
机构
[1] Fluminense Fed Univ, Postgrad Program Med Sci, BR-24033900 Niteroi, RJ, Brazil
[2] Rio de Janeiro Fed Univ, Fac Med, Dept Gynecol & Obstet, Postgrad Program Perinatal Hlth,Matern Sch, Rua Laranjeiras 180, BR-22240000 Rio De Janeiro, Brazil
[3] Hosp Canc 2, Brazilian Natl Canc, BR-20220410 Rio De Janeiro, Brazil
[4] Minas Gerais Fed Univ, Fac Med, Dept Internal Med, BR-30130100 Belo Horizonte, MG, Brazil
[5] Imperial Coll London, Charing Cross Hosp, Charing Cross Gestat Trophoblast Dis Ctr, Dept Med Oncol, London W6 8RF, England
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 10卷 / 02期
关键词
Gestational trophoblastic neoplasia; Chemotherapy; Chorionic gonadotropin; Invasive mole; Choriocarcinoma; Placental site trophoblastic tumor; Epithelioid trophoblastic tumor; COMPLETE HYDATIDIFORM MOLE; UTERINE EVACUATION; 2ND CURETTAGE; DISEASE; MANAGEMENT; RISK; CHEMOTHERAPY; PREGNANCY; TUMORS; WOMEN;
D O I
10.5306/wjco.v10.i2.28
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor (PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases. The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics (FIGO) 2000 criteria: four or more plateaued human chorionic gonadotropin (hCG) concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However, the latter reason for treatment is no longer used by many centers. In addition, GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1 cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate (MTX) or Actinomycin-D (Act-D), can cure about 70% of patients with FIGO/World Health Organization (WHO) prognosis risk score >= 6 (low risk), reserving multiple agent chemotherapy, such as EMA/CO (Etoposide, MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score >= 7 (high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death, allow the healing and maintenance of the reproductive potential of these women.
引用
收藏
页码:28 / 37
页数:10
相关论文
共 56 条
  • [11] Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6 months after uterine evacuation?
    Braga, Antonio
    Torres, Berenice
    Burla, Marcelo
    Maesta, Izildinha
    Sun, Sue Yazaki
    Lin, Lawrence
    Madi, Jose Mauro
    Uberti, Elza
    Viggiano, Mauricio
    Elias, Kevin M.
    Berkowitz, Ross S.
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 143 (03) : 558 - 564
  • [12] Changing Trends in the Clinical Presentation and Management of Complete Hydatidiform Mole Among Brazilian Women
    Braga, Antonio
    Moraes, Valeria
    Maesta, Izildinha
    Amim Junior, Joffre
    de Rezende-Filho, Jorge
    Elias, Kevin
    Berkowitz, Ross
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (05) : 984 - 990
  • [13] Braga A, 2016, J REPROD MED, V61, P224
  • [14] Braga A, 2014, J REPROD MED, V59, P241
  • [15] GESTATIONAL TROPHOBLASTIC DISEASE - COMPARATIVE STUDY OF RESULTS OF THERAPY IN PATIENTS WITH INVASIVE MOLE AND WITH CHORIOCARCINOMA
    BREWER, JI
    ECKMAN, TR
    DOLKART, RE
    TOROK, EE
    WEBSTER, A
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1971, 109 (02) : 335 - &
  • [16] 15 years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage
    Brown, Jubilee
    Naumann, R. Wendel
    Seckl, Michael J.
    Schink, Julian
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 144 (01) : 200 - 207
  • [17] Committee on Practice Bulletins-Gynecology American College of Obstetricians and Gynecologists, 2004, Obstet Gynecol, V103, P1365
  • [18] Dhillon T, 2006, J REPROD MED, V51, P879
  • [19] Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset
    Eysbouts, Y. K.
    Ottevanger, P. B.
    Massuger, L. F. A. G.
    IntHout, J.
    Short, D.
    Harvey, R.
    Kaur, B.
    Sebire, N. J.
    Sarwar, N.
    Sweep, F. C. G. J.
    Seckl, M. J.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1856 - 1861
  • [20] The added value of hysterectomy in the management of gestational trophoblastic neoplasia
    Eysbouts, Y. K.
    Massuger, L. F. A. G.
    IntHout, J.
    Lok, C. A. R.
    Sweep, F. C. G. J.
    Ottevanger, P. B.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 145 (03) : 536 - 542